VSIR and neoplasm: Although the VSIR antagonist’s monotherapy did not show any effect based on preclinical studies, the combination of VSIR and CTLA-4 or PD-1 significantly reduced the number of tumor-recruiting T cells, thereby inducing antitumor responses against squamous cell carcinoma (Kondo et al., 2016).